27 completed, 2 terminated, 1 withdrawn. 12 Phase 2, 11 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 11, Terminated 1 |
| Phase 1 | 11 | Completed 10, Terminated 1 |
| Phase 3 | 6 | Completed 5, Withdrawn 1 |
Follow casopitant: new trials by email Literature Review of casopitant trials Research Report on casopitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Dexamethasone, IV casopitant (placebo), IV casopitant (active) - Cancer, Chemotherapy-Induced Nausea and Vomiting | Phase 3 | Withdrawn | GlaxoSmithKline | 2009-09-01 | 2015-04-17 | |
| A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. Casopitant, Dexamethasone, Placebo - Nausea and Vomiting, Chemotherapy-Induced | Phase 3 | Completed | GlaxoSmithKline | 710 | 2008-03-10 | 2018-01-17 |
| The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects casopitant, dolasetron, granisetron - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Completed | GlaxoSmithKline | 16 | 2007-07-23 | 2017-08-03 |
| The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer Docetaxel, Casopitant/Docetaxel - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Completed | GlaxoSmithKline | 12 | 2007-05-04 | 2017-08-04 |
| A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults Casopitant 150 mg, Ketoconazole, Casopitant 150 mg matching placebo - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Completed | GlaxoSmithKline | 85 | 2007-04-16 | 2017-08-03 |
| A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Completed | GlaxoSmithKline | 37 | 2007-02-19 | 2017-11-13 |
| A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant). GW679769 (Casopitant) oral tablets, Rifampin oral capsules - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Completed | GlaxoSmithKline | 12 | 2006-11-11 | 2017-09-12 |
| A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride - Nausea and Vomiting, Chemotherapy-Induced | Phase 3 | Completed | GlaxoSmithKline | 810 | 2006-11-06 | 2017-08-22 |
| A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers Casopitant (GW679769) oral tablets, Warfarin oral tablets - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Completed | GlaxoSmithKline | 97 | 2006-11-01 | 2017-08-09 |
| Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769] ketoconazole, casopitant 100 mg, Casopitant 50 mg - Nausea and Vomiting, Chemotherapy-Induced | Phase 1 | Completed | GlaxoSmithKline | 15 | 2006-10-20 | 2017-09-12 |
| Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment Casopitant - Vomiting | Phase 1 | Completed | GlaxoSmithKline | 18 | 2006-09-08 | 2017-08-04 |
| Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous - Vomiting, Nausea | Phase 3 | Completed | GlaxoSmithKline | 1840 | 2006-07-01 | 2012-09-10 |
| Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia GW679769 - Sleep Initiation and Maintenance Disorders, Insomnia | Phase 2 | Completed | GlaxoSmithKline | 68 | 2006-05-01 | 2015-04-16 |
| Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women GW679769 (casopitant) - Nausea and Vomiting, Postoperative | Phase 3 | Completed | GlaxoSmithKline | 482 | 2006-03-01 | 2016-10-26 |
| Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women casopitant - Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting | Phase 3 | Completed | GlaxoSmithKline | 515 | 2006-03-01 | 2017-03-23 |
| Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia GW679769 - Sleep Initiation and Maintenance Disorders, Insomnia | Phase 2 | Completed | GlaxoSmithKline | 342 | 2006-01-01 | 2015-04-15 |
| An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia GW679769 oral tablets, Placebo - Nonulcer Dyspepsia | Phase 2 | Completed | GlaxoSmithKline | 13 | 2006-01-01 | 2017-02-08 |
| Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia GW679769 - Sleep Initiation and Maintenance Disorders, Insomnia | Phase 2 | Completed | GlaxoSmithKline | 122 | 2006-01-01 | 2015-04-16 |
| fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder GW679769 - Social Anxiety Disorder | Phase 1 | Completed | GlaxoSmithKline | 57 | 2006-01-01 | 2008-10-16 |
| Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients GW679769 - Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder | Phase 2 | Terminated | GlaxoSmithKline | 1 | 2006-01-01 | 2015-04-17 |
Showing 20 of 30. Sign in to see all of them.
Vomiting (17) · Nausea (14) · Sleep Initiation and Maintenance Disorders (4) · Postoperative Nausea and Vomiting (3) · Depression (2) · Depressive Disorder, Major (2) · Urinary Bladder, Overactive (2) · Colorectal Neoplasms (1) · Depressive Disorder (1) · Fibromyalgia (1) · Lung Neoplasms (1) · Mood Disorders (1) · Neoplasms (1) · Phobia, Social (1) · Renal Insufficiency (1)
GlaxoSmithKline (30)
United States (25) · Canada (9) · Belgium (7) · Germany (7) · Hungary (7) · Philippines (7) · Czechia (6) · Hong Kong (6) · Pakistan (6) · Slovakia (6) · Spain (6) · Thailand (6) · Argentina (5) · Italy (5) · Poland (5)
PMID 19205754, PMID 19428297, PMID 19805683, PMID 19834961, PMID 20220045